ARTICLE | Clinical News
Xenova reports Phase II data of cancer product
October 18, 2000 7:00 AM UTC
In the second of Xenova's three Phase IIa pharmacokinetic trials of XR9576 P-glycoprotein pump ( P-gp) inhibitor to treat multi-drug resistant cancer, Xenova (LSE:XEN; XNVA) said that only minor and p...